NOMAD Power Solutions, Inc. (NMAD) Stock Price & Analysis
NOMAD Power Solutions, Inc. (NMAD) closed at USD 3.81 on Friday, October 23, 2026, up 5.83% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.6; the Oct 23, 2026 session ranged USD 3.5–3.84 on volume of 172,739 shares. Market capitalization is $61.35M, with a 52-week range of USD 2.36–8.38 (NCM). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NMAD.md
Key facts (NMAD)
- Analysts: None.
- Total return with dividends: 1Y -12.0% vs S&P 500 +13.4%; 5Y -79.7% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NMAD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$5.1M | -$8.0M |
| Net income | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.1M | -$8.9M |
| EPS (diluted) | -$5.00 | -$3.99 | -$2.66 | -$1.59 | -$1.26 | — |
| Cash + short-term investments | $4.8M | $5.4M | $4.2M | $1.0M | $5.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NMAD)
P/B 2.6x · Earnings yield -14.55%
Analysts (NMAD)
Consensus None.
Total return (dividends reinvested) (NMAD)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -12.0% | -79.7% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -12.1% | -27.4% |
| Volatility (annualized) | 93.6% | 118.5% |
| Max drawdown | -59.3% (Jun 2026→Sep 2026) | -96.7% (Jan 2022→Jun 2025) |
NMAD suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | GSK | “December 23, 2025 we announced that we are going to expand the enrollment of the trial from 21 to 42 patients in collaboration with GSK,” |
| Competitor | Siemens | “primary competitors in the proton therapy market are IBA Worldwide, Varian Medical Systems (Siemens Healthineers), Hitachi, Mevion” |
Quoted from the company's 10-K filed Mar 31, 2026.
NMAD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 3.81 |
|---|---|
| Change | ▲ 5.83% (up) |
| Previous Close | USD 3.6 |
| Open | USD 3.55 |
| Day Range | USD 3.5 – 3.84 |
| 52-Week Range | USD 2.36 – 8.38 |
| Volume | 172,739 shares |
| Market Cap | $61.35M |
| Exchange | NCM |
Technical Analysis (NMAD)
Nexqual's technical model rates NMAD "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.44 (neutral) |
| vs SMA50 | Below (USD 3.91) |
| MACD | -0.06 (negative) |
Analyst Ratings (NMAD)
Wall Street analysts rate NMAD "None", per Nexqual as of October 24, 2026 at 13:34 UTC.
| Consensus Rating | None |
|---|
Earnings (NMAD)
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (NMAD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.04 |
| Total Cash | $12.67M |
| Total Debt | $1.10M |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financial Health Score (NMAD)
Nexqual rates NOMAD Power Solutions, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 13:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% (last 12 months) |
| Balance Sheet | Strong — $13M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$3M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (NMAD)
| Insider Ownership | +11.51% |
|---|---|
| Institutional Ownership | +12.72% |
| Shares Outstanding | 16.10M |
| Short % of Float | +6.39% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Leadership (NMAD)
NOMAD Power Solutions, Inc. is led by Geordan G. Pursglove, Chairman of the Board of Directors, President & CEO, per Nexqual as of October 24, 2026 at 13:34 UTC.
| Chairman of the Board of Directors, President & CEO | Geordan G. Pursglove |
|---|---|
| Chief Financial Officer | Peter M. Stazzone |
| COO & Director | Chris McKay |
| Director of Sales | Jim Allan |
Major Backers & Investors (NMAD)
Notable institutional backers of NOMAD Power Solutions, Inc. include Legacy Wealth Managment, LLC/ID, Scotia Capital Inc., Fidelity, according to Nexqual as of October 24, 2026 at 13:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Legacy Wealth Managment, LLC/ID | 3.73% |
| Scotia Capital Inc. | 1.76% |
| Fidelity | 0.64% |
| Federation Des Caisses Desjardins Du Quebec | 0.24% |
| Ethos Financial Group, LLC | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.87% |
| Geode Capital | 0.89% |
| BlackRock | 0.47% |
| State Street | 0.47% |
| Northern Trust | 0.17% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From NOMAD Power Solutions, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Liora's proprietary technology, known as LiGHT System (Linac for Image Guided Hadron Therapy), has significant advantages over currently available technologies for treating tumors with proton therapy.
- The Company's ability to stop third parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to which the Company has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities.
Partnerships
- June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute ("NKI") to conduct a Phase 1b clinical trial of the Company's protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F.
- March 31, 2025 we announced we will conduct a new pre-clinical study in collaboration with the NKI to test whether "initiated" cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE's proprietary compound LB-100. as of June 15, 2022, Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KE | Kimball Electronics, Inc. | USD 24.6 | ▼ 1.62% |
| ENVX | Enovix Corporation | USD 2.79 | ▲ 9.41% |
| EOSE | Eos Energy Enterprises, Inc. | USD 1.73 | ▲ 1.17% |
| TE | T1 Energy Inc. | USD 2.29 | ▼ 0.87% |
| ADSE | ADS-TEC ENERGY PLC | USD 9.7 | ▲ 1.57% |
| FCEL | FuelCell Energy, Inc. | USD 11.11 | ▼ 4.06% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt